The Research Ethics Committee for Medicinal Products (CERm/CEIm) at the Clínic Campus is beginning a new chapter with the renewal of its management team and a commitment to continuing to ensure the highest standards of ethical and scientific excellence in all research conducted at the Campus. The new team is committed to consolidating the Committee’s role in safeguarding the rights, safety and well-being of people participating in research studies, while helping to promote rigorous, responsible research that keeps pace with scientific advances.
The new management team is headed by Dr José Tomás Ortiz, a cardiologist at Hospital Clínic Barcelona, as Chair; Dr Jordi Esteve, a haematologist at the hospital, as Vice-Chair; and Dr Lina María Leguízamo-Martínez, a clinical pharmacologist at Hospital Clínic Barcelona, as Head of the Technical Secretariat and Committee Secretary. On the occasion of this change in leadership, the institution would like to express its gratitude to Dr José María Miró, former Chair of the Committee; Dr Julio Delgado, former Vice-Chair; and Dr Lucía Arellano, former Head of the Technical Secretariat, for their dedication, rigour and work throughout their respective terms of office.
A multidisciplinary committee supporting responsible research
The CERm/CEIm is a multidisciplinary body whose main function, in accordance with international research ethics recommendations and current legislation, is to safeguard the rights, safety and well-being of people participating in biomedical research studies.
To fulfil this responsibility, the Committee brings together professionals from a range of fields and disciplines. These include patient representatives, legal professionals specialising in data protection, bioethics experts, nursing professionals, pharmacy and medical device specialists, as well as doctors from various medical specialties, including cardiology, neurology, respiratory medicine, gynaecology and obstetrics, haematology and clinical pharmacology.
This diversity of expertise has recently been strengthened with the addition of oncology specialists and professionals with expertise in cybersecurity and artificial intelligence. This expansion reflects the need to anticipate new developments in biomedical research and ensure that the Committee has the skills required to assess increasingly complex projects.
The CERm/CEIm therefore assesses the methodological, ethical and legal aspects of clinical trials and research projects involving human participants, the use of health data or biological samples.
Essential work to ensure research quality
The Committee’s importance to research activity across the Campus is reflected in its workload over the past year, during which it handled a total of 2,567 submissions. During this period, the CERm/CEIm assessed 814 research projects, 51 clinical trials and 271 amendments.
This volume of activity highlights the Committee’s strategic role in research development and the need to continue evolving to meet researchers’ needs, while maintaining the rigour and ethical safeguards that must underpin every scientific project.
In this context, the new management team has defined three main strategic priorities for the coming years:
- Comprehensively protecting research participants. Maintaining the protection of the rights, safety, well-being, dignity and privacy of people taking part in research studies as a top priority, ensuring that all scientific advances are developed with the highest ethical safeguards.
- Streamlining processes and supporting researchers. Consolidating a Committee that is rigorous but also accessible and approachable, facilitating assessment procedures, improving administrative efficiency and helping research projects progress more smoothly.
- Anticipating new challenges in biomedical research. Adapting assessment criteria and tools to new scientific and technological paradigms, particularly in areas such as big data, artificial intelligence applied to healthcare and cybersecurity.
With this new chapter, the CERm/CEIm reaffirms its commitment to research excellence that is ethically responsible and centred on people. This commitment places participant protection and scientific rigour at the heart of research activity and helps consolidate the Clínic Campus as a leading environment for biomedical research.
